SCHEMBL929138

SCHEMBL929138

N#Cc1cccc(-c2cc(C(=O)O)nc(N)n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.60
ADORA1 P30542 4/20 0.60
XDH P47989 2/20 0.53
ATR Q13535 2/20 0.48
PRKDC P78527 1/20 0.48
F11 P03951 1/20 0.47
PIN1 Q13526 1/20 0.47
SLC22A12 Q96S37 1/20 0.47
PDE4A P27815 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931017 0.81 ADORA2A (0.66) ADORA2AADORA1KDM4ECYP1A2CYP2C9
SCHEMBL1202970 0.80 CTSA (0.54) ADORA2AADORA1XDHATRPRKDC
SCHEMBL930558 0.79 KMO (0.61) ADORA2AADORA1XDHATRPIN1
SCHEMBL19400785 0.78 KMO (0.67) CYP1A2CYP2C19
SCHEMBL2881992 0.77 HSP90AA1 (0.61) ADORA2AADORA1XDHATRKDM4E
SCHEMBL29672835 0.77 HSP90AA1 (0.61) ADORA2AADORA1XDHATRKDM4E
SCHEMBL1357565 0.77 XDH (0.55) ADORA2AADORA1XDHCTSSCTSK
SCHEMBL24412187 0.76 ADORA2A (0.48) ADORA2AADORA1XDHATRPRKDC
SCHEMBL931176 0.76 ADORA2A (1.00) ADORA2AADORA1
SCHEMBL929982 0.76 ADORA2A (0.60) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875600-B2 Pyrimidine compounds as purine receptor antagonist VERNALIS (R&D) LIMITED (GB) 2011-01-25 US disclosed
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide VERNALIS (R & D ) LIMITED (GB) 2007-12-06 US disclosed
EP-1720553-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R&D) LTD (GB) 2006-11-15 EP disclosed
WO-2005079801-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R & D) LTD (GB) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885XDH 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.